Trial Information

Summary: A Phase III Multi-centered, Randomized, Double-blind, Placebo-controlled trial evaluating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis

Official Title
A Phase III Multi-centered, Randomized, Double-blind, Placebo-controlled trial evaluating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis Condition

We are working with Centocor Research & Development, Inc. to conduct a clinical trial of an investigational medication for moderate to severe psoriasis. The medication is injected into the skin once every few months. The study design ensures that all patients receive active study drug during the study period. Participants may receive payment and there will be no charge for study-related office visits or medications.

For additional information, call Kim Raynor, LPN at 609-371-7396

Patient Inclusion Criteria

• Plaque psoriasis which involves at least 10% of body surface area

Patient Exclusion Criteria

• History of cancer (except basal cell skin cancer) History of severe asthma Current or upcoming pregnancy

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:38 AM